These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Genome Editing with CRISPR-Cas9: Can It Get Any Better? Haeussler M; Concordet JP J Genet Genomics; 2016 May; 43(5):239-50. PubMed ID: 27210042 [TBL] [Abstract][Full Text] [Related]
44. Bridge Helix of Cas9 Modulates Target DNA Cleavage and Mismatch Tolerance. Babu K; Amrani N; Jiang W; Yogesha SD; Nguyen R; Qin PZ; Rajan R Biochemistry; 2019 Apr; 58(14):1905-1917. PubMed ID: 30916546 [TBL] [Abstract][Full Text] [Related]
45. Potential pitfalls of CRISPR/Cas9-mediated genome editing. Peng R; Lin G; Li J FEBS J; 2016 Apr; 283(7):1218-31. PubMed ID: 26535798 [TBL] [Abstract][Full Text] [Related]
46. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362 [TBL] [Abstract][Full Text] [Related]
47. Crystal Structure of the Minimal Cas9 from Campylobacter jejuni Reveals the Molecular Diversity in the CRISPR-Cas9 Systems. Yamada M; Watanabe Y; Gootenberg JS; Hirano H; Ran FA; Nakane T; Ishitani R; Zhang F; Nishimasu H; Nureki O Mol Cell; 2017 Mar; 65(6):1109-1121.e3. PubMed ID: 28306506 [TBL] [Abstract][Full Text] [Related]
50. CRISPR/Cas9 in Genome Editing and Beyond. Wang H; La Russa M; Qi LS Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843 [TBL] [Abstract][Full Text] [Related]
51. The Impact of DNA Topology and Guide Length on Target Selection by a Cytosine-Specific Cas9. Tsui TKM; Hand TH; Duboy EC; Li H ACS Synth Biol; 2017 Jun; 6(6):1103-1113. PubMed ID: 28277645 [TBL] [Abstract][Full Text] [Related]
53. Simplified CRISPR-Mediated DNA Editing in Multicellular Eukaryotes. Kumar R; Tiwari K; Saudagar P Methods Mol Biol; 2023; 2575():241-260. PubMed ID: 36301478 [TBL] [Abstract][Full Text] [Related]
54. Single molecule methods for studying CRISPR Cas9-induced DNA unwinding. Okafor IC; Choi J; Ha T Methods; 2022 Aug; 204():319-326. PubMed ID: 34767923 [TBL] [Abstract][Full Text] [Related]
55. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Lin S; Staahl BT; Alla RK; Doudna JA Elife; 2014 Dec; 3():e04766. PubMed ID: 25497837 [TBL] [Abstract][Full Text] [Related]
56. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a. Shin HR; Kweon J; Kim Y Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383 [TBL] [Abstract][Full Text] [Related]
57. Expanding the Biologist's Toolkit with CRISPR-Cas9. Sternberg SH; Doudna JA Mol Cell; 2015 May; 58(4):568-74. PubMed ID: 26000842 [TBL] [Abstract][Full Text] [Related]
58. Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation. Berkhout B; Gao Z; Herrera-Carrillo E Methods Mol Biol; 2021; 2167():205-224. PubMed ID: 32712922 [TBL] [Abstract][Full Text] [Related]
59. Rational guide RNA engineering for small-molecule control of CRISPR/Cas9 and gene editing. Liu X; Xiong W; Qi Q; Zhang Y; Ji H; Cui S; An J; Sun X; Yin H; Tian T; Zhou X Nucleic Acids Res; 2022 May; 50(8):4769-4783. PubMed ID: 35446403 [TBL] [Abstract][Full Text] [Related]
60. Mechanistic insights into the R-loop formation and cleavage in CRISPR-Cas12i1. Zhang B; Luo D; Li Y; Perčulija V; Chen J; Lin J; Ye Y; Ouyang S Nat Commun; 2021 Jun; 12(1):3476. PubMed ID: 34108490 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]